Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 03, 2024 08:30 ET
|
Inozyme Pharma Inc.
Inozyme granted stock options to one new employee to purchase shares of the Company’s common stock as an inducement material to the new employee.
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
April 08, 2024 06:30 ET
|
Inozyme Pharma Inc.
- Favorable safety and immunogenicity profile in ABCC6 Deficiency, with clinical improvements in vascular pathology, visual function and patient reported outcomes (PROs) - - Natural history study...
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 05, 2024 18:00 ET
|
Inozyme Pharma Inc.
BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the...
Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference
April 02, 2024 08:30 ET
|
Inozyme Pharma Inc.
BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for...
Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024
March 26, 2024 08:30 ET
|
Inozyme Pharma Inc.
Inozyme announced that it will host a conference call and webcast on Monday, Apr. 8, 2024 at 8:00 a.m. ET.
Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights
March 12, 2024 08:30 ET
|
Inozyme Pharma Inc.
– Topline data from ongoing Phase 1/2 trials of INZ-701 in adults with ABCC6 Deficiency and ENPP1 Deficiency expected in early April – – Phase 1 trial of INZ-701 in end-stage kidney disease (ESKD)...
Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference
February 26, 2024 08:30 ET
|
Inozyme Pharma Inc.
BOSTON, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the...
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 06, 2024 08:30 ET
|
Inozyme Pharma Inc.
BOSTON, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the...
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 05, 2023 08:30 ET
|
Inozyme Pharma Inc.
BOSTON, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the...
Inozyme Pharma to Participate in Upcoming Investor Conferences
November 09, 2023 08:30 ET
|
Inozyme Pharma Inc.
BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for...